{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:08:46Z","timestamp":1790885326242,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12005-7","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:30:55Z","timestamp":1753191055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization"],"prefix":"10.1038","volume":"15","author":[{"given":"Donovan","family":"Drouillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Halyko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cinquegrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Poimenidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miracle","family":"Emosivbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis C.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Dwinell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"12005_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1110\/ps.041219505","volume":"14","author":"CT Veldkamp","year":"2005","unstructured":"Veldkamp, C. T., Peterson, F. C., Pelzek, A. J. & Volkman, B. F. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 14, 1071\u20131081. https:\/\/doi.org\/10.1110\/ps.041219505 (2005).","journal-title":"Protein Sci."},{"key":"12005_CR2","doi-asserted-by":"publisher","first-page":"ra4","DOI":"10.1126\/scisignal.1160755","volume":"1","author":"CT Veldkamp","year":"2008","unstructured":"Veldkamp, C. T. et al. Structural basis of CXCR4 Sulfotyrosine recognition by the chemokine SDF-1\/CXCL12. Sci. Signal. 1, ra4. https:\/\/doi.org\/10.1126\/scisignal.1160755 (2008).","journal-title":"Sci. Signal."},{"key":"12005_CR3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/cb400274z","volume":"8","author":"JJ Ziarek","year":"2013","unstructured":"Ziarek, J. J. et al. Sulfopeptide probes of the CXCR4\/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery. ACS Chem. Biol. 8, 1955\u20131963. https:\/\/doi.org\/10.1021\/cb400274z (2013).","journal-title":"ACS Chem. Biol."},{"key":"12005_CR4","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/0008-5472.CAN-14-2645","volume":"75","author":"I Roy","year":"2015","unstructured":"Roy, I. et al. Pancreatic Cancer cell migration and metastasis is regulated by Chemokine-Biased agonism and bioenergetic signaling. Cancer Res. 75, 3529\u20133542. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2645 (2015).","journal-title":"Cancer Res."},{"key":"12005_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/mc.22571","volume":"56","author":"I Roy","year":"2017","unstructured":"Roy, I., Getschman, A. E., Volkman, B. F. & Dwinell, M. B. Exploiting agonist biased signaling of chemokines to target cancer. Mol. Carcinog. 56, 804\u2013813. https:\/\/doi.org\/10.1002\/mc.22571 (2017).","journal-title":"Mol. Carcinog."},{"key":"12005_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/onc.2015.139","volume":"35","author":"F Guo","year":"2016","unstructured":"Guo, F. et al. CXCL12\/CXCR4: a symbiotic Bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35, 816\u2013826. https:\/\/doi.org\/10.1038\/onc.2015.139 (2016).","journal-title":"Oncogene"},{"key":"12005_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/bjc.2017.134","volume":"117","author":"H Samarendra","year":"2017","unstructured":"Samarendra, H. et al. A meta-analysis of CXCL12 expression for cancer prognosis. Br. J. Cancer. 117, 124\u2013135. https:\/\/doi.org\/10.1038\/bjc.2017.134 (2017).","journal-title":"Br. J. Cancer"},{"key":"12005_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bjh.16456","volume":"189","author":"EE Ladikou","year":"2020","unstructured":"Ladikou, E. E., Chevassut, T., Pepper, C. J. & Pepper, A. G. Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia. Br. J. Haematol. 189, 815\u2013825. https:\/\/doi.org\/10.1111\/bjh.16456 (2020).","journal-title":"Br. J. Haematol."},{"key":"12005_CR9","doi-asserted-by":"publisher","first-page":"17655","DOI":"10.1073\/pnas.1101133108","volume":"108","author":"LJ Drury","year":"2011","unstructured":"Drury, L. J. et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl. Acad. Sci. U S A. 108, 17655\u201317660. https:\/\/doi.org\/10.1073\/pnas.1101133108 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12005_CR10","doi-asserted-by":"publisher","unstructured":"Ziarek, J. J. et al. Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation. Sci. Signal. 10. https:\/\/doi.org\/10.1126\/scisignal.aah5756 (2017).","DOI":"10.1126\/scisignal.aah5756"},{"key":"12005_CR11","doi-asserted-by":"publisher","unstructured":"Zhang, T. Y. et al. IL-6 Blockade reverses bone marrow failure induced by human acute myeloid leukemia. Sci. Transl Med. 12. https:\/\/doi.org\/10.1126\/scitranslmed.aax5104 (2020).","DOI":"10.1126\/scitranslmed.aax5104"},{"key":"12005_CR12","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins, R. J., Francis, A., Kuchenbauer, F. & Sanford, D. Management of acute myeloid leukemia: A review for general practitioners in oncology. Curr. Oncol. 29, 6245\u20136259. https:\/\/doi.org\/10.3390\/curroncol29090491 (2022).","journal-title":"Curr. Oncol."},{"key":"12005_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","volume":"36","author":"C Recher","year":"2022","unstructured":"Recher, C. et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia 36, 913\u2013922. https:\/\/doi.org\/10.1038\/s41375-021-01425-9 (2022).","journal-title":"Leukemia"},{"key":"12005_CR14","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum, F. R. et al. Age and acute myeloid leukemia. Blood 107, 3481\u20133485. https:\/\/doi.org\/10.1182\/blood-2005-09-3724 (2006).","journal-title":"Blood"},{"key":"12005_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3904\/kjim.2016.244","volume":"32","author":"BS Cho","year":"2017","unstructured":"Cho, B. S., Kim, H. J. & Konopleva, M. Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J. Intern. Med. 32, 248\u2013257. https:\/\/doi.org\/10.3904\/kjim.2016.244 (2017).","journal-title":"Korean J. Intern. Med."},{"key":"12005_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","volume":"11","author":"EA Sison","year":"2013","unstructured":"Sison, E. A., McIntyre, E., Magoon, D. & Brown, P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol. Cancer Res. 11, 1004\u20131016. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0114 (2013).","journal-title":"Mol. Cancer Res."},{"key":"12005_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510. https:\/\/doi.org\/10.1038\/nature10738 (2012).","journal-title":"Nature"},{"key":"12005_CR18","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","volume":"113","author":"B Nervi","year":"2009","unstructured":"Nervi, B. et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206\u20136214. https:\/\/doi.org\/10.1182\/blood-2008-06-162123 (2009).","journal-title":"Blood"},{"key":"12005_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1182\/blood-2015-02-628677","volume":"126","author":"BS Cho","year":"2015","unstructured":"Cho, B. S. et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 126, 222\u2013232. https:\/\/doi.org\/10.1182\/blood-2015-02-628677 (2015).","journal-title":"Blood"},{"key":"12005_CR20","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1038\/cddis.2012.137","volume":"3","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell. Death Dis. 3, e396. https:\/\/doi.org\/10.1038\/cddis.2012.137 (2012).","journal-title":"Cell. Death Dis."},{"key":"12005_CR21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2017.82","volume":"31","author":"M Abraham","year":"2017","unstructured":"Abraham, M. et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16 \u2013 1 expression. Leukemia 31, 2336\u20132346. https:\/\/doi.org\/10.1038\/leu.2017.82 (2017).","journal-title":"Leukemia"},{"key":"12005_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","volume":"103","author":"GJ Roboz","year":"2018","unstructured":"Roboz, G. J. et al. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica 103, 1308\u20131316. https:\/\/doi.org\/10.3324\/haematol.2017.183418 (2018).","journal-title":"Haematologica"},{"key":"12005_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00277-018-3229-5","volume":"97","author":"D Martinez-Cuadron","year":"2018","unstructured":"Martinez-Cuadron, D. et al. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Ann. Hematol. 97, 763\u2013772. https:\/\/doi.org\/10.1007\/s00277-018-3229-5 (2018).","journal-title":"Ann. Hematol."},{"key":"12005_CR24","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","volume":"119","author":"GL Uy","year":"2012","unstructured":"Uy, G. L. et al. A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119, 3917\u20133924. https:\/\/doi.org\/10.1182\/blood-2011-10-383406 (2012).","journal-title":"Blood"},{"key":"12005_CR25","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1038\/bcj.2017.21","volume":"7","author":"GL Uy","year":"2017","unstructured":"Uy, G. L. et al. A phase 1\/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J. 7, e542. https:\/\/doi.org\/10.1038\/bcj.2017.21 (2017).","journal-title":"Blood Cancer J."},{"key":"12005_CR26","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1182\/blood-2022-166748","volume":"140","author":"SJ Segura","year":"2022","unstructured":"Segura, S. J. et al. Double-blind placebo controlled, randomized, multicenter, phase II study to assess the efficacy of the high affinity CXCR4 inhibitor BL-8040 as addition to consolidation therapy in AML by the SAL and OSHO leukemia study groups. Blood 140, 3338\u20133340. https:\/\/doi.org\/10.1182\/blood-2022-166748 (2022).","journal-title":"Blood"},{"key":"12005_CR27","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1038\/srep06610","volume":"4","author":"X Li","year":"2014","unstructured":"Li, X. et al. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo. Sci. Rep. 4, 6610. https:\/\/doi.org\/10.1038\/srep06610 (2014).","journal-title":"Sci. Rep."},{"key":"12005_CR28","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1093\/emboj\/16.23.6996","volume":"16","author":"MP Crump","year":"1997","unstructured":"Crump, M. P. et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and Inhibition of HIV-1. EMBO J. 16, 6996\u20137007. https:\/\/doi.org\/10.1093\/emboj\/16.23.6996 (1997).","journal-title":"EMBO J."},{"key":"12005_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41589-023-01292-8","volume":"19","author":"J Caroli","year":"2023","unstructured":"Caroli, J. et al. A community biased signaling atlas. Nat. Chem. Biol. 19, 531\u2013535. https:\/\/doi.org\/10.1038\/s41589-023-01292-8 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"12005_CR30","doi-asserted-by":"publisher","first-page":"7805","DOI":"10.1074\/jbc.M109.091173","volume":"285","author":"JM Busillo","year":"2010","unstructured":"Busillo, J. M. et al. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J. Biol. Chem. 285, 7805\u20137817. https:\/\/doi.org\/10.1074\/jbc.M109.091173 (2010).","journal-title":"J. Biol. Chem."},{"key":"12005_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1124\/molpharm.120.000192","volume":"99","author":"EV Moo","year":"2021","unstructured":"Moo, E. V., van Senten, J. R., Brauner-Osborne, H. & Moller, T. C. Arrestin-Dependent and -Independent internalization of G Protein-Coupled receptors: methods, mechanisms, and implications on cell signaling. Mol. Pharmacol. 99, 242\u2013255. https:\/\/doi.org\/10.1124\/molpharm.120.000192 (2021).","journal-title":"Mol. Pharmacol."},{"key":"12005_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","volume":"1768","author":"JM Busillo","year":"2007","unstructured":"Busillo, J. M. & Benovic, J. L. Regulation of CXCR4 signaling. Biochim. Biophys. Acta. 1768, 952\u2013963. https:\/\/doi.org\/10.1016\/j.bbamem.2006.11.002 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"12005_CR33","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-16-2919","volume":"23","author":"M Abraham","year":"2017","unstructured":"Abraham, M. et al. Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34(+) cells in healthy volunteers. Clin. Cancer Res. 23, 6790\u20136801. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2919 (2017).","journal-title":"Clin. Cancer Res."},{"key":"12005_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0014-5793(02)03143-5","volume":"527","author":"S Hatse","year":"2002","unstructured":"Hatse, S., Princen, K., Bridger, G., De Clercq, E. & Schols, D. Chemokine receptor Inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527, 255\u2013262. https:\/\/doi.org\/10.1016\/s0014-5793(02)03143-5 (2002).","journal-title":"FEBS Lett."},{"key":"12005_CR35","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1128\/JVI.79.3.1930-1933.2005","volume":"79","author":"X Carnec","year":"2005","unstructured":"Carnec, X., Quan, L., Olson, W. C., Hazan, U. & Dragic, T. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J. Virol. 79, 1930\u20131933. https:\/\/doi.org\/10.1128\/JVI.79.3.1930-1933.2005 (2005).","journal-title":"J. Virol."},{"key":"12005_CR36","doi-asserted-by":"publisher","unstructured":"Kaiser, L. M. et al. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenstrom\u2019s Macroglobulinemia. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13040826 (2021).","DOI":"10.3390\/cancers13040826"},{"key":"12005_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.113.007724","volume":"66","author":"F Bachelerie","year":"2014","unstructured":"Bachelerie, F. et al. International union [corrected]. basic and [corrected].inical pharmacology. [corrected]. LXXXIX. Update [corrected]. [corrected].e [corrected].tended family [corrected]. [corrected].emokine [corrected].ceptors and introducing a new nomenclature for atypical [corrected].emokine [corrected].ceptors. Pharmacol. Rev. 66, 1\u201379. https:\/\/doi.org\/10.1124\/pr.113.007724 (2014).","journal-title":"Pharmacol. Rev."},{"key":"12005_CR38","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1038\/s41467-020-16664-0","volume":"11","author":"M Meyrath","year":"2020","unstructured":"Meyrath, M. et al. The atypical chemokine receptor ACKR3\/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nat. Commun. 11, 3033. https:\/\/doi.org\/10.1038\/s41467-020-16664-0 (2020).","journal-title":"Nat. Commun."},{"key":"12005_CR39","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1523\/JNEUROSCI.08-07-02361.1988","volume":"8","author":"EJ Hess","year":"1988","unstructured":"Hess, E. J., Norman, A. B. & Creese, I. Chronic treatment with dopamine receptor antagonists: behavioral and Pharmacologic effects on D1 and D2 dopamine receptors. J. Neurosci. 8, 2361\u20132370. https:\/\/doi.org\/10.1523\/JNEUROSCI.08-07-02361.1988 (1988).","journal-title":"J. Neurosci."},{"key":"12005_CR40","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1073\/pnas.93.13.6802","volume":"93","author":"MJ Smit","year":"1996","unstructured":"Smit, M. J. et al. Inverse agonism of Histamine H2 antagonist accounts for upregulation of spontaneously active Histamine H2 receptors. Proc. Natl. Acad. Sci. U S A. 93, 6802\u20136807. https:\/\/doi.org\/10.1073\/pnas.93.13.6802 (1996).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12005_CR41","doi-asserted-by":"publisher","first-page":"18448","DOI":"10.1016\/S0021-9258(17)32329-3","volume":"269","author":"M von Zastrow","year":"1994","unstructured":"von Zastrow, M. & Kobilka, B. K. Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization. J. Biol. Chem. 269, 18448\u201318452 (1994).","journal-title":"J. Biol. Chem."},{"key":"12005_CR42","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.18632\/oncotarget.2407","volume":"5","author":"EA Sison","year":"2014","unstructured":"Sison, E. A. et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 Inhibition. Oncotarget 5, 8947\u20138958. https:\/\/doi.org\/10.18632\/oncotarget.2407 (2014).","journal-title":"Oncotarget"},{"key":"12005_CR43","doi-asserted-by":"publisher","first-page":"20397","DOI":"10.1074\/jbc.274.29.20397","volume":"274","author":"M Bouaboula","year":"1999","unstructured":"Bouaboula, M., Dussossoy, D. & Casellas, P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J. Biol. Chem. 274, 20397\u201320405. https:\/\/doi.org\/10.1074\/jbc.274.29.20397 (1999).","journal-title":"J. Biol. Chem."},{"key":"12005_CR44","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.20041385","volume":"201","author":"HE Broxmeyer","year":"2005","unstructured":"Broxmeyer, H. E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307\u20131318. https:\/\/doi.org\/10.1084\/jem.20041385 (2005).","journal-title":"J. Exp. Med."},{"key":"12005_CR45","doi-asserted-by":"publisher","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 e1224. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031 (2019).","DOI":"10.1016\/j.cell.2019.01.031"},{"key":"12005_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/leu.2016.329","volume":"31","author":"C Zhou","year":"2017","unstructured":"Zhou, C. et al. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia 31, 1196\u20131205. https:\/\/doi.org\/10.1038\/leu.2016.329 (2017).","journal-title":"Leukemia"},{"key":"12005_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/leu.2014.259","volume":"29","author":"PM Korthuis","year":"2015","unstructured":"Korthuis, P. M. et al. CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia. Leukemia 29, 625\u2013635. https:\/\/doi.org\/10.1038\/leu.2014.259 (2015).","journal-title":"Leukemia"},{"key":"12005_CR48","doi-asserted-by":"publisher","first-page":"e3132","DOI":"10.1038\/cddis.2017.548","volume":"8","author":"K Mattes","year":"2017","unstructured":"Mattes, K., Berger, G., Geugien, M., Vellenga, E. & Schepers, H. CITED2 affects leukemic cell survival by interfering with p53 activation. Cell. Death Dis. 8, e3132. https:\/\/doi.org\/10.1038\/cddis.2017.548 (2017).","journal-title":"Cell. Death Dis."},{"issue":"2","key":"12005_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccr.2012.06.027","volume":"22","author":"M Kawahara","year":"2013","unstructured":"Kawahara, M. et al. H2.0-like homeobox (HLX) regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell. 22 (2), 194\u2013208. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.027 (2013).","journal-title":"Cancer Cell."},{"issue":"1","key":"12005_CR50","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1038\/s41467-018-05311-4","volume":"9","author":"I Piragyte","year":"2018","unstructured":"Piragyte, I. et al. A metabolic interplay coordinate by HLX regulate myeloid differentiation and AML through partly overlapping pathways. Nat. Commun. 9 (1), 3090. https:\/\/doi.org\/10.1038\/s41467-018-05311-4 (2018).","journal-title":"Nat. Commun."},{"issue":"12","key":"12005_CR51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41422-022-00735-6","volume":"32","author":"CL Hu","year":"2022","unstructured":"Hu, C. L. & Et Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia. Cell. Res. 32 (12), 1105\u20131123. https:\/\/doi.org\/10.1038\/s41422-022-00735-6 (2022).","journal-title":"Cell. Res."},{"issue":"6","key":"12005_CR52","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1101\/gr.273961.120","volume":"31","author":"A Pokhilko","year":"2021","unstructured":"Pokhilko, A. et al. Targeted single-cell RNA sequencing of transcription factors enhance the identification of cell types and trajectories. Genome Res. 31 (6), 1069\u20131081. https:\/\/doi.org\/10.1101\/gr.273961.120 (2021).","journal-title":"Genome Res."},{"key":"12005_CR53","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S Muller-Dott","year":"2023","unstructured":"Muller-Dott, S. et al. Expanding the coverage of Regulons from high-confidence prior knowledge for accurate Estimation of transcription factor activities. Nucleic Acids Res. 51, 10934\u201310949. https:\/\/doi.org\/10.1093\/nar\/gkad841 (2023).","journal-title":"Nucleic Acids Res."},{"key":"12005_CR54","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2019004613","volume":"136","author":"R Takeda","year":"2020","unstructured":"Takeda, R. et al. HHEX promotes myeloid transformation in Cooperation with mutant ASXL1. Blood 136, 1670\u20131684. https:\/\/doi.org\/10.1182\/blood.2019004613 (2020).","journal-title":"Blood"},{"key":"12005_CR55","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2159-8290.CD-18-1391","volume":"9","author":"E Loizou","year":"2019","unstructured":"Loizou, E. et al. A Gain-of-Function p53-Mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1. Cancer Discov. 9, 962\u2013979. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1391 (2019).","journal-title":"Cancer Discov"},{"key":"12005_CR56","doi-asserted-by":"publisher","first-page":"24515","DOI":"10.1074\/jbc.M200889200","volume":"277","author":"WB Zhang","year":"2002","unstructured":"Zhang, W. B. et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4\u00a0C are weak partial agonists. J. Biol. Chem. 277, 24515\u201324521. https:\/\/doi.org\/10.1074\/jbc.M200889200 (2002).","journal-title":"J. Biol. Chem."},{"key":"12005_CR57","doi-asserted-by":"publisher","unstructured":"Rebolledo-Bustillo, M. et al. Structural basis of the binding mode of the antineoplastic compound motixafortide (BL-8040) in the CXCR4 chemokine receptor. Int. J. Mol. Sci. 24. https:\/\/doi.org\/10.3390\/ijms24054393 (2023).","DOI":"10.3390\/ijms24054393"},{"key":"12005_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-biophys-051013-022942","volume":"46","author":"I Kufareva","year":"2017","unstructured":"Kufareva, I., Gustavsson, M., Zheng, Y., Stephens, B. S. & Handel, T. M. What do structures tell Us about chemokine receptor function and antagonism?? Annu. Rev. Biophys. 46, 175\u2013198. https:\/\/doi.org\/10.1146\/annurev-biophys-051013-022942 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"12005_CR59","doi-asserted-by":"publisher","unstructured":"Stephens, B. S., Ngo, T., Kufareva, I. & Handel, T. M. Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis. Sci. Signal. 13. https:\/\/doi.org\/10.1126\/scisignal.aay5024 (2020).","DOI":"10.1126\/scisignal.aay5024"},{"key":"12005_CR60","doi-asserted-by":"publisher","first-page":"47136","DOI":"10.1074\/jbc.M307850200","volume":"278","author":"JO Trent","year":"2003","unstructured":"Trent, J. O. et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. 278, 47136\u201347144. https:\/\/doi.org\/10.1074\/jbc.M307850200 (2003).","journal-title":"J. Biol. Chem."},{"key":"12005_CR61","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1038\/s41467-023-41488-z","volume":"14","author":"S Vales","year":"2023","unstructured":"Vales, S. et al. Discovery and pharmacophoric characterization of chemokine network inhibitors using phage-display, saturation mutagenesis and computational modelling. Nat. Commun. 14, 5763. https:\/\/doi.org\/10.1038\/s41467-023-41488-z (2023).","journal-title":"Nat. Commun."},{"key":"12005_CR62","doi-asserted-by":"publisher","first-page":"11251","DOI":"10.1021\/bi800965m","volume":"47","author":"C Seibert","year":"2008","unstructured":"Seibert, C. et al. Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases. Biochemistry 47, 11251\u201311262. https:\/\/doi.org\/10.1021\/bi800965m (2008).","journal-title":"Biochemistry"},{"key":"12005_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev.pharmtox.48.113006.094646","volume":"48","author":"A Marchese","year":"2008","unstructured":"Marchese, A., Paing, M. M., Temple, B. R. S. & Trejo, A. G-protein coupled receptor sorting to endosomes and lysosomes. Annu. Rev. Pharmacol. Toxicol. 48, 601\u2013629. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094646 (2008).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"12005_CR64","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s42003-024-07157-7","volume":"7","author":"VR Robleto","year":"2024","unstructured":"Robleto, V. R., Zhuo, Y., Crecelius, J. M., Benzow, S. & Marchese, A. SNX9 family mediates Barrestin-independent GPCR endocytosis. Commun. Biol. 7 (1), 1455. https:\/\/doi.org\/10.1038\/s42003-024-07157-7 (2024).","journal-title":"Commun. Biol."},{"key":"12005_CR65","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","volume":"113","author":"Z Zeng","year":"2009","unstructured":"Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 Inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215\u20136224. https:\/\/doi.org\/10.1182\/blood-2008-05-158311 (2009).","journal-title":"Blood"},{"key":"12005_CR66","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cncr.33338","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur, G. et al. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study. Cancer 127, 1246\u20131259. https:\/\/doi.org\/10.1002\/cncr.33338 (2021).","journal-title":"Cancer"},{"key":"12005_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fonc.2018.00369","volume":"8","author":"P Boddu","year":"2018","unstructured":"Boddu, P. et al. Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed\/refractory acute myeloid leukemia. Front. Oncol. 8, 369. https:\/\/doi.org\/10.3389\/fonc.2018.00369 (2018).","journal-title":"Front. Oncol."},{"key":"12005_CR68","doi-asserted-by":"publisher","first-page":"e0176057","DOI":"10.1371\/journal.pone.0176057","volume":"12","author":"A Van Hout","year":"2017","unstructured":"Van Hout, A., D\u2019Huys, T., Oeyen, M., Schols, D. & Van Loy, T. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 12, e0176057. https:\/\/doi.org\/10.1371\/journal.pone.0176057 (2017).","journal-title":"PLoS One"},{"key":"12005_CR69","doi-asserted-by":"publisher","first-page":"1184014","DOI":"10.3389\/fimmu.2023.1184014","volume":"14","author":"P Grudzien","year":"2023","unstructured":"Grudzien, P., Neufeld, H., Ebe Eyenga, M. & Gaponenko, V. Development of tolerance to chemokine receptor antagonists: current paradigms and the need for further investigation. Front. Immunol. 14, 1184014. https:\/\/doi.org\/10.3389\/fimmu.2023.1184014 (2023).","journal-title":"Front. Immunol."},{"key":"12005_CR70","doi-asserted-by":"publisher","unstructured":"Hitchinson, B. et al. Biased antagonism of CXCR4 avoids antagonist tolerance. Sci. Signal. 11. https:\/\/doi.org\/10.1126\/scisignal.aat2214 (2018).","DOI":"10.1126\/scisignal.aat2214"},{"key":"12005_CR71","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1091\/mbc.e10-02-0169","volume":"21","author":"R Malik","year":"2010","unstructured":"Malik, R. & Marchese, A. Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Mol. Biol. Cell. 21, 2529\u20132541. https:\/\/doi.org\/10.1091\/mbc.e10-02-0169 (2010).","journal-title":"Mol. Biol. Cell."},{"issue":"9","key":"12005_CR72","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.jbc.2022.102351","volume":"298","author":"Y Zhuo","year":"2022","unstructured":"Zhuo, Y., Crecelius, J. M. & Marchese, A. G protein-coupled receptor kinase phosphorylation of distal C-tail sites specifies Barrestin1-mediated signaling by chemokine receptor CXCR4. J. Biol. Chem. 298 (9), 102351. https:\/\/doi.org\/10.1016\/j.jbc.2022.102351 (2022).","journal-title":"J. Biol. Chem."},{"key":"12005_CR73","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1074\/jbc.M112.394064","volume":"288","author":"JJ Ziarek","year":"2013","unstructured":"Ziarek, J. J. et al. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus. J. Biol. Chem. 288, 737\u2013746. https:\/\/doi.org\/10.1074\/jbc.M112.394064 (2013).","journal-title":"J. Biol. Chem."},{"key":"12005_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.sbi.2016.05.021","volume":"38","author":"JM Antos","year":"2016","unstructured":"Antos, J. M., Truttmann, M. C. & Ploegh, H. L. Recent advances in sortase-catalyzed ligation methodology. Curr. Opin. Struct. Biol. 38, 111\u2013118. https:\/\/doi.org\/10.1016\/j.sbi.2016.05.021 (2016).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"12005_CR75","doi-asserted-by":"publisher","unstructured":"Gutjahr, J. C. et al. The dimeric form of CXCL12 binds to atypical chemokine receptor 1. Sci. Signal. 14. https:\/\/doi.org\/10.1126\/scisignal.abc9012 (2021).","DOI":"10.1126\/scisignal.abc9012"},{"key":"12005_CR76","doi-asserted-by":"publisher","first-page":"G844","DOI":"10.1152\/ajpgi.00112.2003","volume":"286","author":"MB Dwinell","year":"2004","unstructured":"Dwinell, M. B., Ogawa, H., Barrett, K. E. & Kagnoff, M. F. SDF-1\/CXCL12 regulates cAMP production and ion transport in intestinal epithelial cells via CXCR4. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G844\u2013850. https:\/\/doi.org\/10.1152\/ajpgi.00112.2003 (2004).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"12005_CR77","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1091\/mbc.e08-03-0308","volume":"20","author":"D Bhandari","year":"2009","unstructured":"Bhandari, D., Robia, S. L. & Marchese, A. The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction. Mol. Biol. Cell. 20, 1324\u20131339. https:\/\/doi.org\/10.1091\/mbc.e08-03-0308 (2009).","journal-title":"Mol. Biol. Cell."},{"key":"12005_CR78","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/bs.mie.2015.10.004","volume":"570","author":"A Marchese","year":"2016","unstructured":"Marchese, A. Monitoring chemokine receptor trafficking by confocal Immunofluorescence microscopy. Methods Enzymol. 570, 281\u2013292. https:\/\/doi.org\/10.1016\/bs.mie.2015.10.004 (2016).","journal-title":"Methods Enzymol."},{"key":"12005_CR79","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.RA118.005991","volume":"294","author":"A Caballero","year":"2019","unstructured":"Caballero, A., Mahn, S. A., Ali, M. S., Rogers, M. R. & Marchese, A. Heterologous regulation of CXCR4 lysosomal trafficking. J. Biol. Chem. 294, 8023\u20138036. https:\/\/doi.org\/10.1074\/jbc.RA118.005991 (2019).","journal-title":"J. Biol. Chem."},{"key":"12005_CR80","doi-asserted-by":"publisher","unstructured":"Stauffer, W., Sheng, H. & Kim, H. N.  EzColocalization: An ImageJ plugin for visualizing and measuring colocalization in cells and organisms. Sci. Rep. 8 (1), 15764. https:\/\/doi.org\/10.1038\/s41598-018-33592-8 (2018).","DOI":"10.1038\/s41598-018-33592-8"},{"key":"12005_CR81","doi-asserted-by":"publisher","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048  (2021).","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"12005_CR82","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat. Methods. 16, 1289\u20131296. https:\/\/doi.org\/10.1038\/s41592-019-0619-0 (2019).","journal-title":"Nat. Methods"},{"key":"12005_CR83","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","volume":"10","author":"M Finak","year":"2015","unstructured":"Finak, M. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 10, 278. https:\/\/doi.org\/10.1186\/s13059-015-0844-5 (2015).","journal-title":"Genome Biol."},{"key":"12005_CR84","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"Percie du Sert","year":"2020","unstructured":"Percie du Sert. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18, e3000411. https:\/\/doi.org\/10.1371\/journal.pbio.3000411 (2020).","journal-title":"PLoS Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12005-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:05:08Z","timestamp":1757268308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12005-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12005"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12005-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MBD and FP have financial interests in Protein Foundry, LLC and Xlock Biosciences, Inc. The remaining authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26625"}}